How leukemia changes the heart's energy use
Regulation of cardiac metabolism during Leukemia
This work looks at how leukemia-linked molecules harm heart cells in people with acute myeloid leukemia and survivors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11291314 on NIH RePORTER |
What this research studies
From a patient's point of view, researchers will trace how mutations common in AML (like TET2 and IDH2) cause blood cells to release abnormal metabolites such as D-2-hydroxyglutarate that can reach the heart. They will measure these oncometabolite levels and examine heart cell energy pathways and gene regulation using metabolic assays and epigenetic profiling methods including ATAC-seq. The team will use laboratory models and patient-derived samples to see how reduced α-ketoglutarate signaling leads to changes in heart structure and function. The goal is to connect the leukemia-related biochemical changes to the heart remodeling observed during disease and after remission.
Who could benefit from this research
Good fit: Ideal candidates would be people with acute myeloid leukemia or survivors, especially those with TET2 or IDH2 mutations or evidence of clonal hematopoiesis.
Not a fit: People without leukemia, without the specific metabolic or mutation signals described, or with heart disease from unrelated causes are unlikely to get direct benefit from this project.
Why it matters
Potential benefit: If successful, this could point to new ways to protect the heart in people with AML or a history of clonal hematopoiesis and reduce post-cancer heart failure.
How similar studies have performed: Early laboratory work has shown the oncometabolite D-2-hydroxyglutarate can disrupt cardiac metabolism, but translating that finding into patient therapies is still new.
Where this research is happening
Los Angeles, United States
- Cedars-Sinai Medical Center — Los Angeles, United States (Active)
Researchers
- Principal investigator: Karlstaedt, Anja — Cedars-Sinai Medical Center
- Study coordinator: Karlstaedt, Anja
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.